NRC Health (NRC): Net Income
$11.60M
Year ended 2025-12-31
$5.86M
Trailing 12 months to 2026-06-30
-28.5%
3-year compound annual growth
-20.8%
5-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.60M | -53.2% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $24.78M | -20.0% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $30.97M | -2.6% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $31.80M | -15.1% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $37.47M | +0.6% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $37.26M | +15.0% | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | $32.41M | +7.9% | 2022-03-04, From 2019-01-01 |
| 2018-12-31 | $30.05M | +31.0% | 2021-03-05, From 2018-01-01 |
| 2017-12-31 | $22.94M | +11.8% | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | $20.52M | n/a | 2019-03-08, From 2016-01-01 |
| No annual figure between 2013-12-31 and 2016-12-31. | |||
| 2013-12-31 | $15.48M | +2.8% | 2014-03-04, From 2013-01-01 |
| 2012-12-31 | $15.07M | +30.3% | 2014-03-04, From 2012-01-01 |
| 2011-12-31 | $11.56M | +36.1% | 2014-03-04, From 2011-01-01 |
| 2010-12-31 | $8.50M | +0.1% | 2013-03-01, From 2010-01-01 |
| 2009-12-31 | $8.49M | n/a | 2012-03-01, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| NRC Health (NRC) | 2025-12-31 | $11.60M | -53.2% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$44.63M | n/m |
| OmniAb, Inc. (OABI) | 2025-12-31 | -$64.78M | n/m |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | -$12.43M | n/m |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $451.12M | +11.6% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | -$14.91M | n/m |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | -$142.16M | n/m |
| Incyte Corp (INCY) | 2025-12-31 | $1.29B | n/m |
| Absci Corp (ABSI) | 2025-12-31 | -$115.18M | n/m |
Compare NRC, MXCT, OABI, FOXO side by side · Screen every company in Services-Commercial Physical & Biological Research ↗